» Articles » PMID: 18675900

Dietary Oxyresveratrol Prevents Parkinsonian Mimetic 6-hydroxydopamine Neurotoxicity

Overview
Date 2008 Aug 5
PMID 18675900
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Oxyresveratrol (OXY) is a polyhydroxylated stilbene existing in mulberry. Increasing lines of evidence have shown its neuroprotective effects against Alzheimer disease and stroke. However, little is known about its neuroprotective effect in Parkinson disease (PD). Owing to its antioxidant activity, blood-brain barrier permeativity, and water solubility, we hypothesized that OXY may exert neuroprotective effects against parkinsonian mimetic 6-hydroxydopamine (6-OHDA) neurotoxicity. Neuroblastoma SH-SY5Y cells have long been used as dopaminergic neurons in PD research. We found that both pretreatment and posttreatment with OXY on SH-SY5Y cells significantly reduced the release of lactate dehydrogenase, the activity of caspase-3, and the generation of intracellular reactive oxygen species triggered by 6-OHDA. Compared to resveratrol, OXY exhibited a wider effective dosage range. We proved that OXY could penetrate the cell membrane by HPLC analysis of cell extracts. These results suggest that OXY may act as an intracellular antioxidant to reduce oxidative stress induced by 6-OHDA. Western blot analysis demonstrated that OXY markedly attenuated 6-OHDA-induced phosphorylation of JNK and c-Jun. Furthermore, we proved that OXY increased the basal levels of SIRT1, which may disclose new pathways accounting for the neuroprotective effects of OXY. Taken together, our results suggest OXY, a dietary phenolic compound, as a potential nutritional candidate for protection against neurodegeneration in PD.

Citing Articles

Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis.

Xiang L, Li Q, Guan Z, Wang G, Yu X, Zhang X Front Pharmacol. 2025; 15:1527286.

PMID: 39881871 PMC: 11775479. DOI: 10.3389/fphar.2024.1527286.


Development of dihydrooxyresveratrol-loaded nanostructured lipid carriers for safe and effective treatment of hyperpigmentation.

Mikled P, Chavasiri W, Khongkow M Sci Rep. 2024; 14(1):29211.

PMID: 39587280 PMC: 11589685. DOI: 10.1038/s41598-024-80671-0.


Exploration of Nutraceutical Potentials of Isorhapontigenin, Oxyresveratrol and Pterostilbene: A Metabolomic Approach.

Dai Y, Wang J, Yang Y, Jin H, Liu F, Liu H Int J Mol Sci. 2024; 25(20).

PMID: 39456808 PMC: 11507072. DOI: 10.3390/ijms252011027.


Untargeted metabolomics reveal pathways associated with neuroprotective effect of oxyresveratrol in SH-SY5Y cells.

Mahamud N, Songvut P, Muangnoi C, Rodsiri R, Dahlan W, Tansawat R Sci Rep. 2023; 13(1):20385.

PMID: 37989867 PMC: 10663518. DOI: 10.1038/s41598-023-47558-y.


Analysis of phenolic compounds in Parkinson's disease: a bibliometric assessment of the 100 most cited papers.

Perdigao J, Teixeira B, Baia-da-Silva D, Nascimento P, Lima R, Rogez H Front Aging Neurosci. 2023; 15:1149143.

PMID: 37205057 PMC: 10185771. DOI: 10.3389/fnagi.2023.1149143.